Business
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee. Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development
About this update from Traws Pharma, Inc.
[{"type":"text","content":"BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee. Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.","length":602,"tagName":"p"},{"type":"image","alt":"TransCode Therapeutics, Inc. logo (PRNewsfoto/TransCode Therapeutics, Inc.)","displaySize":"","headline":null,"caption":"TransCode Therapeutics, Inc. logo (PRNewsfoto/TransCode Therapeutics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":58,"url":"https://media.zenfs.com/en/prnewswire.com/b0561ee1cbd7c692705f747a1a2c23a8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xcCTGMwRUnjgvJmiy6SfWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b0561ee1cbd7c692705f747a1a2c23a8","width":400,"height":58}},"href":"https://mma.prnewswire.com/media/2843185/TransCode_Therapeutics_Inc.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We are delighted to welcome Jack to TransCode's Board of Directors," said Philippe P. Calais, CEO, TransCode Therapeutics. "Jack's wide and unique operational, financial, and strategic expertise — as well as his successes leading through transformative growth — will be a powerful asset as TransCode advances its RNA and immuno-oncology pipeline."","length":376,"tagName":"p"},{"type":"text","content":"Mr. Stover currently serves as Chairman of the Board of Traws Pharma Inc., a specialty pharmaceutical company focused on anti-virals and oncology. He led the merger of Traws with Onconova Therapeutics Inc and was a Director and Chairman of the Audit Committee of Onconova since 2016. From March 2021 until July 2025, he served as CEO and Director of NorthView Acquisition Corp a special purpose acquisition corporation and subsequently has been a director of Profusa, Inc. a digital health company developing tissue integrated biosensors th...